Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01141283 · ClinicalTrials.gov registry record · Phase 3
Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase
A Phase 3 study of Osteoarthritis, sponsored by Purdue Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 290
- Enrollment target
- 20
- Study locations
NCT01141283 is a Phase 3 study of Osteoarthritis that has completed, run by Purdue Pharma. The registered enrollment target is 290 participants, below the 816-participant average among 135 other Osteoarthritis trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT01141283, a Phase 3 study of Osteoarthritis, has completed, sponsored by Purdue Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 290 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the extension phase is to evaluate the long-term safety and tolerability of buprenorphine transdermal system (BTDS).
Conditions Studied
Interventions
- DRUG Buprenorphine transdermal patch
Study Locations (20)
Florida
- Research Facility - Atlantis
- Allergy, Asthma, Arthritis & Lung - Daytona Beach
- University Clinical Research Deland - DeLand
- Research Facility - Jupiter
- Coastal Medical Research - Orange City
- Research Facility - Plantation
- Research Facility - West Palm Beach
Arizona
- Vista Medical Research Inc. - Mesa
- Arthrocare, Arthritis Care and Research - Phoenix
- Arizona Rheumatology Ctr and Phoenix Ctr for Clinical Research - Phoenix
- Arizona Research Center - Phoenix
- Research Facility - Tucson
California
- Advanced Pain Medicine - Bakersfield
- Orange County Clinical Research - Cypress
- San Diego Arthritis & Osteoporosis Medical Clinic - San Diego
- Research Facility - San Diego
- Research Facility - San Francisco
Colorado
- Research Facility - Denver
- Research Facility - Westminster
Connecticut
- Research Facility - Bridgeport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2003-04 |
| Est. Completion | 2004-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01141283
The ClinicalTrials.gov registry entry for NCT01141283 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 816-participant average among 135 other Osteoarthritis trials with a reported enrollment target (64% lower). The listed sponsor is Purdue Pharma, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine transdermal patch is the first listed.
NCT01141283 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT01141283 about?
NCT01141283 is a clinical study titled "Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase". The purpose of the extension phase is to evaluate the long-term safety and tolerability of buprenorphine transdermal system (BTDS).
What is the current status of trial NCT01141283?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 290 participants. The study started on 2003-04. Estimated completion is 2004-07.
What conditions does trial NCT01141283 study?
This clinical trial studies the following conditions: Osteoarthritis.
What interventions are being tested in trial NCT01141283?
The interventions under investigation include: Buprenorphine transdermal patch (DRUG).
Who is sponsoring clinical trial NCT01141283?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01141283 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Beat Pain Better Trial
RECRUITING · Phase 3
-
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
RECRUITING · Phase 3
-
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
COMPLETED · Phase 3
-
Allograft Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe
COMPLETED · Phase 3
-
Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.